MaxCyte (NASDAQ:MXCT) Rating Reiterated by Stephens

MaxCyte (NASDAQ:MXCT)‘s stock had its “overweight” rating reaffirmed by Stephens in a report released on Tuesday, Benzinga reports. They presently have a $11.00 price target on the stock. Stephens’ price objective would indicate a potential upside of 194.12% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. William Blair restated an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th. BTIG Research dropped their price objective on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 13th.

MaxCyte Stock Down 1.6 %

Shares of NASDAQ MXCT opened at $3.74 on Tuesday. MaxCyte has a twelve month low of $2.45 and a twelve month high of $5.55. The company has a market cap of $390.46 million, a PE ratio of -10.11 and a beta of 1.34. The business’s 50 day moving average price is $4.25 and its two-hundred day moving average price is $4.32.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The business had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $15.60 million. As a group, research analysts anticipate that MaxCyte will post -0.53 EPS for the current fiscal year.

Insider Transactions at MaxCyte

In other news, Director John Joseph Johnston sold 5,000 shares of the stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the transaction, the director now directly owns 120,583 shares of the company’s stock, valued at approximately $617,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. purchased a new position in shares of MaxCyte during the 4th quarter valued at $29,000. Victory Capital Management Inc. bought a new position in MaxCyte in the third quarter valued at $31,000. Johnson Investment Counsel Inc. purchased a new stake in MaxCyte during the third quarter valued at about $34,000. Aigen Investment Management LP bought a new stake in MaxCyte during the third quarter worth about $44,000. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of MaxCyte by 47,100.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after purchasing an additional 11,775 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.